Shanghai Henlius Biotech (HKG:2696) said that China's National Medical Products Administration (NMPA) approved an application for a Phase 2 clinical trial of HLX79 injection in combination with Hanlikang for the treatment of active glomerulonephritis, according to a filing made on Tuesday with the Hong Kong bourse.
HLX79 is a sialidase fusion protein made by combining a human sialidase enzyme with a human monoclonal antibody.
Hanlikang is approved in Mainland China for non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and rheumatoid arthritis (RA).
The pharmaceutical company's shares were up 3% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.